Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.66 |
| ▸ | NEK2 | P51955 | 4/20 | 0.66 |
| ▸ | CSF1R | P07333 | 3/20 | 0.66 |
| ▸ | KDR | P35968 | 3/20 | 0.66 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.66 |
| ▸ | STK3 | Q13188 | 3/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.66 |
| ▸ | BRSK1 | Q8TDC3 | 3/20 | 0.66 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.66 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.66 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.66 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.66 |
| ▸ | PIM1 | P11309 | 2/20 | 0.66 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.66 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.66 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.66 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.66 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3739454 | 0.93 | PLK1 (0.66) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3739899 | 0.90 | PLK1 (0.53) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3734449 | 0.90 | PLK1 (0.82) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3747967 | 0.84 | PLK1 (0.73) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3734894 | 0.84 | PLK1 (0.53) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3739950 | 0.84 | PLK1 (0.81) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3734905 | 0.83 | PLK1 (0.82) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3745124 | 0.83 | PLK1 (0.64) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3746667 | 0.81 | PLK1 (0.64) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3736022 | 0.81 | PLK1 (0.61) | PLK1NEK2CSF1RKDRLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158267-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| EP-2424546-B1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORP (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20140275128-A1 | METHOD OF PROVIDING OCULAR NEUROPROTECTION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130217643-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | disclosed |
| US-8470800-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-06-25 | — | — | US | disclosed |
| US-8273890-B2 | Thiophene-imidazopyridines | 4SC AG (DE) | 2012-09-25 | — | — | US | disclosed |
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100279970-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2009003911-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | PIKFYVE, PIP4K2B, PIP5K1B | PLK1 642/4885NEK2 2328/4885CSF1R 2699/4885 |
| US-20100279970-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE6G, NDUFB7, PDE3A | PLK1 1914/4885NEK2 1946/4885CSF1R 4066/4885 |
| US-20160158267-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | ADORA2A, ADORA1, PDE6C | PLK1 3599/4885NEK2 2936/4885CSF1R 1908/4885 |
| US-20140275128-A1 | METHOD OF PROVIDING OCULAR NEUROPROTECTION | ALDH1A2, GAP43, ALDH1A3 | PLK1 2895/4885NEK2 1035/4885CSF1R 3725/4885 |
| US-20130217643-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE6G, NDUFB7, PDE3A | PLK1 1914/4885NEK2 1946/4885CSF1R 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.